BCR-ABL
8 drugsBCR-ABL1 Fusion Gene (Philadelphia Chromosome)
Predictive biomarker for patient selection in 8 indications
Understanding BCR-ABL
What it means: BCR-ABL results from a translocation creating the Philadelphia chromosome. The fusion protein has constitutive tyrosine kinase activity.
Why it matters: Tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, ponatinib) revolutionized CML treatment, achieving long-term remissions.
Testing: Tested via cytogenetics, FISH, or RT-PCR. Quantitative PCR monitors treatment response (molecular response levels).
8
Approved Drugs
8
Indications
7
Companies
BCR-ABL is a precision-medicine biomarker linked to 8 FDA-approved targeted drugs from 7 companies, spanning 8 indications including Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia. Explore the targeted therapies, indications, testing methods, and companies developing BCR-ABL drugs below.
Search BCR-ABL Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting BCR-ABL
BCR-ABL Indications
Chronic Myeloid Leukemia Acute Lymphoblastic Leukemia Chronic Myelogenous Leukemia Myelodysplastic/Myeloproliferative Diseases Systemic Mastocytosis Hypereosinophilic Syndrome Chronic Eosinophilic Leukemia Dermatofibrosarcoma Protuberans